Harrow Health Inc – (HROW, +1, Dec 23rd)
Four insiders bought a total of $725,000 of stock on the 21-22nd December at approx $13.40. Most notably Mark Baum (CEO since 2012, founder) bought $325,000 increasing his stake by 2% in his first clean purchase on record despite a long tenure and Martin Makary (Non-Executive since March 2022) bought $334,000 having only just joined the board. He is Chief of Islet Transplant Surgery at The Johns Hopkins Hospital.
Lawrence Horn (Director since 2020) bought $25,000 in his first buy since joining and Andrew Boll (CFO since 2015, joined 2011) bought $34,000 in his first clean purchase since joining. The company raised $25m at $10.52 on the 14th of December (Opaleye Management who are 13% shareholders bought $4.5m) which may have triggered these purchases but they do appear to be clean open-market buys.
We are ranking the stock +1.